Product Information
EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $114.5030 per EA under NDC 00378544093. Its NADAC has been published 33 times since Feb 18, 2026.
FDA first approved this application on May 20, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB
Emtricitabine, Rilpivirine, Tenofovir Disoproxil FumarateStrength
200; 25; 300 mg/1; mg/1; mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378544093
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATEApproval Type
Generic (ANDA)
FDA Application
ANDA208452FDA Approved
5/20/2025
TE Code
AB
On Market Since
5/27/2025
Pharmacological Classes
Price Statistics
The NADAC for EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB has been published 33 times since Feb 18, 2026, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $114.5030 per EA |
|---|---|
| All-time high | $114.9924 (Jul 15, 2026) |
| All-time low | $114.5030 (Aug 19, 2026) |
| 52-week high | $114.9924 |
| 52-week low | $114.5030 |
| Median price | $114.8597 |
| Average price | $114.8147 |
| Largest weekly change | -0.3% (Jul 22, 2026) |
| Weeks tracked | 33 |
| Tracking since | Feb 18, 2026 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Emtricitabine, Rilpivirine, Tenofovir Disoproxil Fumarate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Emtricitabine, Rilpivirine, Tenofovir Disoproxil Fumarate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB, manufactured by Mylan Pharmaceuticals Inc., is $114.5030 per EA (NDC 00378544093), effective Sep 30, 2026.
How has the price of EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB changed over time?
Over the history we have for it, the NADAC for EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB has held within roughly two percent of its current level. It has been tracked across 33 weekly CMS publications since Feb 18, 2026.
What are the highest and lowest recorded NADAC prices for EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB?
Since Feb 18, 2026, the NADAC for EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB has ranged from a low of $114.5030 (Aug 19, 2026) to a high of $114.9924 (Jul 15, 2026), with a median of $114.8597 per EA.
Are there cheaper alternatives to EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB?
No other NADAC-published product currently shares the active ingredient and strength of EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB?
EMTRICITABINE-RILPIVIRINE-TENOFOVIR DIS FUM 200-25-300 MG TB (NDC 00378544093) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.